Literature DB >> 8067763

Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.

M A Jacobson1, B Polsky, D Causey, R Davis, W Tong, J J O'Donnell, B D Kuppermann, M H Heinemann, J Feinberg, P Lizak.   

Abstract

The pharmacodynamic relationship between a range of foscarnet exposure measurements obtained from studying nine patients receiving ongoing maintenance therapy for cytomegalovirus retinitis and a range of efficacy values (days to retinitis progression) obtained by independent examination of serial retinal photographs from the same nine patients was analyzed. In the resulting proportional hazards models, the foscarnet area under the concentration-time curve approached statistical significance (P = 0.11) as a predictor of decreased risk of retinitis progression.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8067763      PMCID： PMC188177          DOI： 10.1128/AAC.38.5.1190

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Authors:  A M Taburet; C Katlama; C Blanshard; G Zorza; D Gazzard; E Dohin; B G Gazzard; C Frostegard; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.

Authors:  J Sjövall; A Karlsson; S Ogenstad; E Sandström; M Saarimäki
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

3.  A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

Authors:  M A Jacobson; D Causey; B Polsky; D Hardy; M Chown; R Davis; J J O'Donnell; B D Kuppermann; M H Heinemann; G N Holland
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

4.  Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

Authors:  M A Jacobson; J J O'Donnell; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  Foscarnet nephrotoxicity: mechanism, incidence and prevention.

Authors:  G Deray; F Martinez; C Katlama; B Levaltier; H Beaufils; M Danis; M Rozenheim; A Baumelou; E Dohin; M Gentilini
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

6.  A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.

Authors:  A G Palestine; M A Polis; M D De Smet; B F Baird; J Falloon; J A Kovacs; R T Davey; J J Zurlo; K M Zunich; M Davis
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

7.  Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.

Authors:  C Katlama; E Dohin; E Caumes; I Cochereau-Massin; C Brancon; M Robinet; O Rogeaux; R Dahan; M Gentilini
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

8.  Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.

Authors:  K J Pettersson; T Nordgren; D Westerlund
Journal:  J Chromatogr       Date:  1989-03-24
  8 in total
  1 in total

Review 1.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.